Metropolitan Life Insurance Co. NY lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 2.8% in the second quarter, Holdings Channel reports. The fund owned 413,769 shares of the company’s stock after selling 11,810 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Merck & Co., Inc. were worth $25,116,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Baldwin Investment Management LLC bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $381,000. Albion Financial Group UT raised its stake in Merck & Co., Inc. by 17.6% in the 2nd quarter. Albion Financial Group UT now owns 73,625 shares of the company’s stock valued at $4,469,000 after acquiring an additional 11,022 shares during the period. Tower Research Capital LLC TRC raised its stake in Merck & Co., Inc. by 33,861.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 135,846 shares of the company’s stock valued at $8,246,000 after acquiring an additional 135,446 shares during the period. Marshall Wace LLP bought a new stake in Merck & Co., Inc. in the 2nd quarter valued at $2,027,000. Finally, New England Asset Management Inc. raised its stake in Merck & Co., Inc. by 12.0% in the 2nd quarter. New England Asset Management Inc. now owns 62,950 shares of the company’s stock valued at $3,821,000 after acquiring an additional 6,750 shares during the period. 72.31% of the stock is owned by hedge funds and other institutional investors.
In related news, Chairman Kenneth C. Frazier sold 279,850 shares of the firm’s stock in a transaction dated Tuesday, October 2nd. The stock was sold at an average price of $72.07, for a total value of $20,168,789.50. Following the sale, the chairman now directly owns 971,800 shares of the company’s stock, valued at $70,037,626. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Adam H. Schechter sold 107,360 shares of Merck & Co., Inc. stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $70.18, for a total value of $7,534,524.80. Following the sale, the executive vice president now directly owns 100,000 shares in the company, valued at $7,018,000. The disclosure for this sale can be found here. Over the last three months, insiders have sold 929,360 shares of company stock worth $64,370,599. 0.32% of the stock is currently owned by insiders.
MRK stock opened at $72.35 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.61. The firm has a market cap of $193.64 billion, a price-to-earnings ratio of 18.18, a PEG ratio of 2.22 and a beta of 0.81. Merck & Co., Inc. has a fifty-two week low of $52.83 and a fifty-two week high of $72.89.
Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Friday, July 27th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.03. The company had revenue of $10.47 billion for the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. Merck & Co., Inc.’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.01 EPS. As a group, equities analysts expect that Merck & Co., Inc. will post 4.28 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, October 5th. Stockholders of record on Monday, September 17th were issued a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a dividend yield of 2.65%. The ex-dividend date of this dividend was Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 48.24%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.